Anna Strzepa1,2, Cody J Gurski1, Landon J Dittel3, Marian Szczepanik2, Kirkwood A Pritchard4, Bonnie N Dittel1,5. 1. Versiti Blood Research Institute, Milwaukee, WI, United States. 2. Department of Medical Biology, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland. 3. Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, United States. 4. Department of Surgery, Division of Pediatric Surgery, Medical College of Wisconsin, Milwaukee, WI, United States. 5. Deparment of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI, United States.
Abstract
Background: Allergic contact dermatitis (ACD) is a common skin disorder affecting an estimated 15-20% of the general population. The mouse model of ACD is contact hypersensitivity (CHS), which consists of two phases: induction and elicitation. Although neutrophils are required for both CHS disease phases their mechanisms of action are poorly understood. Neutrophils release myeloperoxidase (MPO) that through oxidation of biomolecules leads to cellular damage. Objectives: This study investigated mechanisms whereby MPO contributes to CHS pathogenesis. Methods: CHS was induced in mice using oxazolone (OX) as the initiating hapten applied to the skin. After 7 days, CHS was elicited by application of OX to the ear and disease severity was measured by ear thickness and vascular permeability in the ear. The role of MPO in the two phases of CHS was determined utilizing MPO-deficient mice and a specific MPO inhibitor. Results: During the CHS induction phase MPO-deficiency lead to a reduction in IL-1β production in the skin and a subsequent reduction in migratory dendritic cells (DC) and effector T cells in the draining lymph node. During the elicitation phase, inhibition of MPO significantly reduced both ear swelling and vascular permeability. Conclusion: MPO plays dual roles in CHS pathogenesis. In the initiation phase MPO promotes IL-1β production in the skin and activation of migratory DC that promote effector T cell priming. In the elicitation phase MPO drives vascular permeability contributing to inflammation. These results indicate that MPO it could be a potential therapeutic target for the treatment of ACD in humans.
Background: Allergic contact dermatitis (ACD) is a common skin disorder affecting an estimated 15-20% of the general population. The mouse model of ACD is contact hypersensitivity (CHS), which consists of two phases: induction and elicitation. Although neutrophils are required for both CHS disease phases their mechanisms of action are poorly understood. Neutrophils release myeloperoxidase (MPO) that through oxidation of biomolecules leads to cellular damage. Objectives: This study investigated mechanisms whereby MPO contributes to CHS pathogenesis. Methods:CHS was induced in mice using oxazolone (OX) as the initiating hapten applied to the skin. After 7 days, CHS was elicited by application of OX to the ear and disease severity was measured by ear thickness and vascular permeability in the ear. The role of MPO in the two phases of CHS was determined utilizing MPO-deficient mice and a specific MPO inhibitor. Results: During the CHS induction phase MPO-deficiency lead to a reduction in IL-1β production in the skin and a subsequent reduction in migratory dendritic cells (DC) and effector T cells in the draining lymph node. During the elicitation phase, inhibition of MPO significantly reduced both ear swelling and vascular permeability. Conclusion:MPO plays dual roles in CHS pathogenesis. In the initiation phase MPO promotes IL-1β production in the skin and activation of migratory DC that promote effector T cell priming. In the elicitation phase MPO drives vascular permeability contributing to inflammation. These results indicate that MPO it could be a potential therapeutic target for the treatment of ACD in humans.
Authors: Anne Dudeck; Jan Dudeck; Julia Scholten; Anke Petzold; Sangeetha Surianarayanan; Anja Köhler; Katrin Peschke; David Vöhringer; Claudia Waskow; Thomas Krieg; Werner Müller; Ari Waisman; Karin Hartmann; Matthias Gunzer; Axel Roers Journal: Immunity Date: 2011-06-24 Impact factor: 31.745
Authors: Shicheng Yang; Luca Gattinoni; Gattinoni Luca; Fang Liu; Yun Ji; Zhiya Yu; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan Journal: Cancer Immunol Immunother Date: 2011-02-09 Impact factor: 6.968
Authors: Hao Zhang; Hao Xu; Dorothee Weihrauch; Deron W Jones; Xigang Jing; Yang Shi; David Gourlay; Keith T Oldham; Cheryl A Hillery; Kirkwood A Pritchard Journal: J Lipid Res Date: 2013-08-16 Impact factor: 5.922
Authors: Yonggang Ma; Xiaoyuan Yang; Victor Chatterjee; Jamie E Meegan; Richard S Beard; Sarah Y Yuan Journal: Front Immunol Date: 2019-05-09 Impact factor: 7.561
Authors: Rogério Marchete; Sarah Oliveira; Leonardo Bagne; Jennyffer Ione de Souza Silva; Ana Paula Valverde; Andrea Aparecida de Aro; Mariana Moreira Figueira; Marcio Fronza; Thainá Mikaela Bressam; Vivian Fernandes Furletti de Goes; Fernanda Oliveira de Gaspari de Gaspi; Gláucia Maria Tech Dos Santos; Thiago Antônio Moretti Andrade Journal: Inflammopharmacology Date: 2021-09-21 Impact factor: 4.473
Authors: Savannah D Neu; Anna Strzepa; Dustin Martin; Mary G Sorci-Thomas; Kirkwood A Pritchard; Bonnie N Dittel Journal: Antioxidants (Basel) Date: 2021-08-25